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Variations in Cholesterol Management Practices of U.S. Physicians
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Boston, Massachusetts
Objectives. This study sought to evaluate national cholesterol
management practices of U.S. physicians.
Background. Past studies show that nonclinical factors affect
physician practices. We tested the hypothesis that physician and
patient characteristics influence cholesterol management.
Methods. We used a stratified, random sample of 2,332 office-
based physicians providing 56,215 visits to adults in the 1991–
1992 National Ambulatory Medical Care Surveys. We investigated
physicians’ reporting of cholesterol-related screening, counseling
or medications during office visits and used multiple logistic
regression to assess independent predictors.
Results. An estimated 1.12 billion adult office visits occurred in
1991 and 1992 (95% confidence interval 1.06 to 1.18 billion). For
the 1.03 billion visits by patients without reported hyperlipidemia,
cholesterol screening (2.8% of visits) and counseling (1.2%) were
not frequent. The likelihood of screening increased with older age,
cardiovascular disease risk factors, white race and private insur-
ance. We estimate that only 1 in 12 adults received cholesterol
screening annually. In the 85 million visits by patients with
hyperlipidemia, cholesterol testing was reported in 22.9%, choles-
terol counseling in 34.4% and lipid-lowering medications in 23.1%.
Testing was more likely in diabetic and nonobese patients. Coun-
seling was more likely with younger age, cardiovascular disease
and private insurance. Medications use was associated with
cardiovascular disease, Northeast region of the United States,
nonobese patients and visits to internists. Physician practices did
not differ by patient gender.
Conclusions. Although clinical conditions strongly influence
cholesterol management, the appropriateness of variations noted
by payment source, geographic region and physician specialty
deserve further evaluation. These variations and the low esti-
mated volume of services suggest that physicians have not fully
adopted recommended cholesterol management practices.
(J Am Coll Cardiol 1997;29:139–46)
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In the United States, cardiovascular disease accounts for
945,000 annual deaths (41% of all deaths) (1) and contributes
to substantial morbidity, including 6 million hospital admis-
sions annually (2). Hyperlipidemia continues to represent an
important modifiable risk factor for the development and
progression of cardiovascular disease (3–6). An estimated 29%
of Americans have lipid abnormalities sufficient to warrant
treatment with at least dietary modifications (7).
Great effort has been expended in developing and promot-
ing clinical guidelines for the screening and treatment of lipid
abnormalities (8–10). Before the first 1988 National Choles-
terol Education Program (NCEP) recommendations, a trend
toward more aggressive management of hyperlipidemia had
already been noted in this country (11). Specific guidelines for
cholesterol testing, dietary counseling and pharmacologic
treatment have emphasized activities provided both to patients
without known cardiovascular disease (primary prevention)
and to those already diagnosed with cardiovascular disease
(secondary prevention). However, despite considerable efforts
at encouraging appropriate cholesterol management, little is
known about how U.S. physicians actually practice. Several
small studies suggest inadequate adherence to existing guide-
lines (12–14). Information on current practices is essential for
identifying obstacles to optimal preventive practices.
Several factors have been shown in past studies to influence
cholesterol management services. Internists and cardiologists
provide more counseling than other specialties (15,16). The
data of Cherkin et al. (17) from 1976 to 1977 indicated that
general internists were more likely than family physicians to
order cholesterol testing. The 1990 National Health Interview
Survey (18) found that patients of higher socioeconomic status
reported a higher likelihood of cholesterol testing, with college
education and white race associated with higher rates of any
past testing. Although these studies suggest a role for nonclini-
cal factors in cholesterol-related physician practices, they fail
to provide definitive, national data that are physician based
and adjusted for potential confounders.
The current study uses data from the National Ambulatory
Medical Care Surveys (NAMCS) to investigate patterns of
cholesterol management by U.S. physicians. In particular, we
evaluate the independent influence of gender, race, age,
clinical diagnoses and physician specialty on testing, counseling
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and medication practices in patients with and without known
lipid abnormalities. A key hypothesis of this study is that
factors other than clinical condition exert an influence on
cholesterol management and may represent modifiable barri-
ers to appropriate practices.
Methods
Data source. Data for this study come from the 1991 and
1992 NAMCS conducted by the National Center for Health
Statistics (19–22). These ongoing, annual surveys of U.S.
physicians select office-based, patient-care medical doctors and
doctors of osteopathy from the American Medical Association
and American Osteopathic Association listings of all practicing
physicians in the United States. From these lists, office-based,
patient-care physicians were selected by random, stratified
sampling by geographic area and specialty. In 1991 and 1992, a
total of 2,912 physicians of 4,029 selected (72%) agreed to
participate in the study. For each participating physician, a
random week during each year was selected for systematic
sampling of 20% to 100% of their patient visits. Information on
68,401 visits was available through these surveys. The sample
of physicians seeing adults consisted of 2,332 physicians report-
ing on 56,215 visits.
For each patient visit, physicians or their office staff com-
pleted encounter forms detailing the specific clinical services
provided during the visit, as well as patient demographics,
diagnoses, current medications, physician characteristics and
visit characteristics. The NAMCS was designed to provide a
sample of patient visits from which national estimates can be
derived. With each visit record, the National Center for Health
Statistics provides a visit weight calculated from the physician
and visit sampling rates, adjusted for nonresponse. Statistical
aggregation using these visit weights allows national volumes
of clinical activities to be estimated among the universe of U.S.
office-based, patient-care physicians. To reflect the uncertainty
associated with these estimates, 95% confidence intervals were
derived from National Center for Health Statistics relative
standard error estimates (21,22). Validation studies performed
in earlier years have confirmed the general accuracy of the
NAMCS data (23). Missing data are limited to ;5% of most
data fields (22). The data exclude outpatient care provided in
health centers, some hospital outpatient departments, emer-
gency rooms and by nonphysician providers.
The NAMCS includes information on diagnostic testing,
medications, counseling and procedures. Among other services,
physicians specifically indicated whether they had provided
“counseling/education: cholesterol reduction” and “diagnostic/
screening services: cholesterol measure” (22). Cholesterol coun-
seling includes any advice related to cholesterol, including dietary
advice, although general dietary advice was assessed through a
separate indicator. Cholesterol measurement encompasses labo-
ratory tests for either a cholesterol panel or total cholesterol
alone. We analyzed the use of services related to cholesterol
management, including counseling and screening in patients
without known hyperlipidemia and counseling, monitoring and
lipid-lowering medication use in hyperlipidemic patients. Patterns
for patients without known hyperlipidemia were based on 52,598
visits, whereas those for hyperlipidemic patients were based on
3,617 visits.
The presence of hyperlipidemia, atherosclerotic cardiovas-
cular disease, hypertension, obesity, diabetes and smoking
were coded if any one of the following indicators were re-
corded on visit records: a specific NAMCS patient problem
code (for smoking, hyperlipidemia, obesity and hypotension);
an appropriate NAMCS “reason for visit” code (24) (for
atherosclerosis, smoking, obesity, diabetes mellitus and hyper-
tension); or an appropriate International Classification of
Disease (ICD-9-CM) diagnostic code (25) (for atherosclerosis,
smoking, hypertension, obesity and hyperlipidemia). In the
absence of other indicators, patients also were defined as
having hyperlipidemia if reported to be taking lipid-lowering
medications. American Medical Association primary physician
specialty designations (22) were used to categorize physicians
as cardiologists, other internists, family physicians and general
practitioners and all other physicians. Geographic area was
defined by the four U.S. Census regions of West, South,
Northeast and Midwest. Private insurance was defined as
private or health maintenance organization coverage.
Statistical methods. We separately analyzed national cho-
lesterol management practices for patients with and without
known hyperlipidemia. A first step was to calculate national
estimates of the volume of cholesterol-related services pro-
vided. These estimates made use of the visit weights assigned
to each visit record. To test our hypotheses regarding practice
patterns, we investigated the independent predictors of the
likelihood of these services being provided at a given visit.
Using multiple logistic regression, we determined the influ-
ence of a set of independent predictor variables on the odds
that patients received cholesterol management services. Anal-
ysis was carried out using the SAS LOGISTIC procedure,
version 6.10 (26,27). Independent variables included physician
specialty, patient gender, patient age, patient race, presence of
cardiovascular disease and its risk factors (smoking, obesity,
hypertension and diabetes), expected payment source and
census region. As an alternative statistical approach, physician-
level regression models also were developed using the SAS
GLM procedure, version 6.10 (26). These models accounted
for the lack of independence among visits to individual physi-
cians by predicting the natural logarithm of the odds of a
particular physician providing a prevention service as a func-
tion of the above series of independent variables each defined
Abbreviations and Acronyms
CI 5 confidence interval
NAMCS 5 National Ambulatory Medical Care Survey
NCEP 5 National Cholesterol Education Program
NHANES III 5 National Health and Nutrition Examination Survey,
Third Survey
OR 5 odds ratio
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at the physician level (e.g., proportion of a physician’s visits
that were by women) (28). Results of these alternative models
were consistent with visit-level logistic regression models and
are not presented.
The NAMCS provides a cross-sectional description of
physician practices that does not allow the longitudinal expe-
rience of patients to be assessed. The unit of analysis is the
patient visit, rather than the patient. Patients visiting physi-
cians more frequently may have a lower likelihood of receiving
testing or counseling at any given visit. For these patients,
visit-based rates of services may understate their actual use of
preventive services. We evaluated this potential bias by ana-
lyzing practices in two types of visits: first visits to physicians
and general medical examinations. Because they are unlikely
to be repeated on the same individual in a given year, these
types of visits are more likely to represent self-contained
episodes of care. Analysis of these visits provides a method of
validating patterns observed for the entire sample.
Although the NAMCS provides national data on the vol-
ume of cholesterol management services, it lacks denominator
information needed to assess how extensively these services are
being provided to the general population of individuals with
and without known hyperlipidemia. To extend the usefulness
of the NAMCS data, we combined it with other data sources
that allow estimation of the number of Americans with and
without known hyperlipidemia. The third National Health and
Nutrition Examination Survey (NHANES III) (7) estimates
that 29% of adults in the United States have lipid abnormali-
ties. To derive a national estimate of adults with known lipid
abnormalities, we used the estimate from the Atherosclerosis
Risk in Communities (ARIC) study (29) that only 42% of
those with lipid abnormalities are aware of their condition. We
thus estimated that of 188 million adults in the United States
in 1991 (30), there were 23 million American adults with
known lipid abnormalities and 165 million without known lipid
abnormalities. Combining NAMCS numerator estimates with
these population denominators allows calculation of 1) annual
screening rates for Americans without known hyperlipidemia,
and 2) annual screening and counseling rates for Americans
with hyperlipidemia. Although combining data from NAMCS
and NHANES II has potential hazards, cautious use of this
strategy allows several critical aspects of national cholesterol
management practices to be assessed.
Results
Of the 1.12 billion estimated visits to U.S. office-based
physicians in 1991 and 1992 (95% confidence interval [CI] 1.07
to 1.16 billion), 42 million included cholesterol counseling
(95% CI 40 to 45 million, 3.7%), and 49 million included
cholesterol tests (95% CI 46 to 52 million, 4.4%). In addition,
20 million visits (95% CI 18 to 22 million, 1.8%) were made by
patients taking lipid-lowering medications. Although choles-
terol management services were concentrated among the 85
million visits (95% CI 81 to 89 million) by patients with lipid
abnormalities (8% of total visits), services also were provided
to patients without identified hyperlipidemia. As expected,
patients with cardiovascular disease (4% of all visits) also
received a larger than proportional share of cholesterol-related
testing, counseling and medications (Table 1).
Patients without reported hyperlipidemia. Cholesterol-
related services provided during the 1.03 billion visits (95% CI
0.99 to 1.07 billion) to patients without known hyperlipidemia
in 1991 and 1992 focused on cholesterol screening. In this
population, 29 million cholesterol tests were ordered (95% CI
27 to 32 million, 2.8% of these visits). Cholesterol counseling
in the absence of known lipid abnormalities was not frequent
(12 million episodes, 95% CI 10 to 14 million, 1.2% of visits),
although it accounted for 29% of all reported episodes of
counseling.
Table 1. U.S. Office Visits With Cholesterol Testing, Cholesterol Counseling and Lipid-Lowering Medications: National Ambulatory Medical
Care Survey, 1991 and 1992
All Patient Visits
Visits With Cholesterol
Testing Ordered
Visits With Cholesterol
Counseling Provided
Visits With Lipid-Lowering
Medications
No.
(millions) %
No.
(millions)
Rate of
Testing
(%)
No.
(millions)
Rate of
Counseling
(%)
No.
(millions)
Rate of
Medication Use
(%)
No known hyperlipidemia
Without CVD 998 89.4 27.4 2.7 10.6 1.1
With CVD 33 2.9 2.0 5.9 1.7 5.3
Total 1,031 92.3 29.4 2.8 12.3 1.2
With hyperlipidemia
Without CVD 72 6.5 16.3 22.6 23.4 32.4 14.6 20.2
With CVD 13 1.2 3.2 24.5 6.0 45.0 5.1 38.9
Total 85 7.7 19.5 22.9 29.4 34.4 19.7 23.1
Total
Without CVD 1,070 95.9 43.7 4.1 34.0 3.2 14.6 1.4
With CVD 46 4.1 5.2 11.3 7.7 16.7 5.1 11.2
Grand total 1,116 100.0 48.9 4.4 41.7 3.7 19.7 1.8
CVD 5 cardiovascular disease.
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Specific patient and physician characteristics made choles-
terol screening more likely. Cholesterol screening was more
likely in visits by patients.35 years old (3.3%) than in younger
patients (1.8%, p, 0.001). White patients (2.9%) were slightly
more likely to be screened than nonwhites (2.5%, p 5 0.034).
Cardiovascular disease and its risk factors made screening
more likely. In particular, diabetes (7.9%, p , 0.001), cardio-
vascular disease (5.9%, p , 0.001) and obesity (5.5%, p ,
0.001) made screening more likely. Cholesterol screening also
was more common in patients with (3.1%) than without private
insurance (2.6%, p , 0.001). Cholesterol screening was more
likely in the Northeast region of the country (3.8%) than in
other regions (2.5%, p , 0.001). Physician specialty also
affected screening patterns, with cardiologists (5.5%) and
other internists (6.1%) reporting more screening than family
physicians and general practitioners (3.3%) and all other
physicians (1.5%, p , 0.001). The impact of each of these
variables on the likelihood of cholesterol screening was statis-
tically significant within a multiple logistic regression analysis
controlling for gender, age, race, region, cardiovascular disease
and its risk factors, payment source and physician specialty
(Table 2).
Among patients without hyperlipidemia, patient age and
clinical condition were the strongest predictors of cholesterol
counseling. The youngest (0.4%) and oldest (1.1%) patients
were less likely to be counseled than patients 35 to 69 years old
(1.7%, p , 0.001). Cardiovascular disease was associated with
a 5.3% rate of counseling compared with 1.1% in those without
it (p , 0.001). In addition, the presence of obesity (3.4%, p ,
0.001), diabetes (3.0%, p , 0.001) and hypertension (3.5%,
p, 0.001) made counseling more likely. In contrast to patterns
of cholesterol screening, nonwhites were more likely to receive
cholesterol counseling (1.7%) than whites (1.0%, p , 0.001).
Visits to cardiologists were five times more likely to involve
counseling (6.1%) than visits to other physicians (1.1%, p ,
0.001). These effects persisted and were statistically significant
with multivariate adjustment for potential confounders (Table
2).
We estimated annual cholesterol screening rates by com-
bining the above NAMCS volume estimates with population
estimates derived from NHANES III and other sources. As
described above, we estimated a 1991 population of 23 million
adults with and 165 million adults without known hyperlipid-
emia. Applying our NAMCS estimate of 29 million cholesterol
tests to those without known lipid abnormalities in 2 years to
this 165 million denominator implies an average annual
screening rate of only 8.8%/year in this population.
Patients with reported hyperlipidemia. Although visits by
patients with reported lipid abnormalities comprised only 8%
of all visits in 1991 and 1992, 71% of all cholesterol counseling
and 40% of all cholesterol testing took place during these
visits. Cholesterol testing occurred during 20 million visits
Table 2. Likelihood of Cholesterol Services in Adults Without Known Hyperlipidemia: National
Ambulatory Medical Care Survey, 1991 and 1992
Percent of
Visits Without
Hyperlipidemia
Cholesterol Testing:
Adjusted Odds Ratio*
(95% CI)
Cholesterol Counseling:
Adjusted Odds Ratio*
(95% CI)
Male gender 36.7 0.78 (0.70–0.87) 1.12 (0.95–1.32)
Age (yr)
,35 28.5 0.73 (0.61–0.88) 0.75 (0.53–1.07)
35–49 26.2 1.00 (0.85–1.18) 2.39 (1.85–3.09)
50–69 25.8 1.14 (0.98–1.32) 2.01 (1.59–2.54)
701 20.2 1.00 (reference) 1.00 (reference)
White race 82.8 1.37 (1.18–1.59) 0.76 (0.63–0.92)
CVD 3.2 1.25 (0.99–1.57) 2.68 (2.05–3.51)
Diabetes 3.6 1.79 (1.49–2.15) 1.17 (0.88–1.56)
Obesity 8.6 1.58 (1.36–1.83) 2.21 (1.82–2.69)
Hypertension 14.7 1.33 (1.16–1.51) 2.57 (2.15–3.07)
Smoking 12.8 1.14 (0.98–1.32) 1.10 (0.88–1.37)
Private insurance 52.0 1.45 (1.30–1.62) 0.96 (0.81–1.13)
Specialty
Cardiology 1.8 1.35 (1.00–1.83) 2.15 (1.55–2.97)
Internal medicine 22.0 1.69 (1.49–1.92) 1.02 (0.84–1.24)
Other specialties 49.7 0.33 (0.28–0.38) 0.29 (0.23–0.37)
FP/GP 26.3 1.00 (reference) 1.00 (reference)
Region
South 29.9 0.60 (0.51–0.70) 0.80 (0.63–1.01)
Midwest 23.9 0.83 (0.72–0.95) 0.71 (0.57–0.89)
West 23.6 0.77 (0.66–0.89) 1.10 (0.88–1.38)
Northeast 22.6 1.00 (reference) 1.00 (reference)
*Independent effect of each variable controlling for all other variables listed, estimated by multiple logistic regression.
CVD 5 cardiovascular disease; CI 5 confidence interval; FP/GP 5 family physicians and general practitioners.
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(95% CI 18.2 to 21.8, 22.9%). Cholesterol counseling was
provided during 29 million visits (95% CI 27.0 to 31.0, 34.4%).
In addition, 20 million visits were made by patients reported to
be taking lipid-lowering medications (95% CI 18.1 to 21.9,
23.1%).
Cholesterol testing in patients with hyperlipidemia was less
strongly influenced by patient characteristics than cholesterol
screening in those without known hyperlipidemia. The pres-
ence of diabetes made testing more likely (28.1%, p 5 0.002),
although the presence of obesity (17.5%, p , 0.001) made
testing less likely. Surprisingly, cardiovascular disease itself did
not increase the likelihood of testing. Private insurance made
testing more likely (24.6% vs. 21.3% without private insurance,
p 5 0.012), and patients in the Northeast were the most likely
to be tested (30.0% vs. 20.7% other regions, p, 0.001). Family
physicians and general practitioners (22.2%) and cardiologists
(18.9%) were less likely to monitor cholesterol levels than
internists (28.5%, p , 0.001). These patterns of cholesterol
testing persisted and were statistically significant within a
multiple logistic regression model accounting for potential
confounders (Table 3).
Cholesterol counseling during visits by patients with lipid
abnormalities was more likely in patients,35 years old (42.9%
vs. 34.0%.35 years old, p5 0.016). Counseling also was more
likely in the presence of cardiovascular disease (45.0%, p ,
0.001), diabetes (44.8%, p , 0.001), hypertension (37.2%, p ,
0.001) and obesity (41.8%, p, 0.001). As with patients without
hyperlipidemia, nonwhites were more likely to be counseled
(43.3%) than whites (32.4%, p , 0.001). Privately insured
patients showed a nonsignificant tendency to be counseled
(35.6%) more than those without private insurance (33.2%,
p 5 0.089). Counseling was more likely in the Northeast
(40.0%) than in other regions (32.6%, p , 0.001). Internists
(38.7%), cardiologists (35.3%) and family physicians and gen-
eral practitioners (36.4%) were more likely to counsel their
patients than other physicians (16.2%, p , 0.001). These
effects were confirmed to be statistically significant by multiple
logistic regression, including the association of private insur-
ance with an increased likelihood of cholesterol counseling
(Table 3).
Lipid-lowering medications were more likely to be reported
for patients with cardiovascular disease (38.9% vs. 20.2%
without, p , 0.001). Obese patients were considerably less
likely to be receiving medications (16.2%) than the nonobese
(26.3%, p , 0.001). Privately insured patients (25.5%) were
more likely to be taking medications than patients without
private insurance (20.9%, p , 0.001). Physicians in the North-
east were more likely to use medications (30.3%) than those in
Table 3. Likelihood of Cholesterol Services in Adults With Hyperlipidemia: National Ambulatory
Medical Care Survey, 1991 and 1992
Percent of
Visits With
Hyperlipidemia
Cholesterol
Testing:
Adjusted
Odds Ratio*
(95% CI)
Cholesterol
Counseling:
Adjusted
Odds Ratio*
(95% CI)
Lipid-Lowering
Medications:
Adjusted
Odds Ratio*
(95% CI)
Male gender 38.4 1.09 (0.93–1.27) 1.08 (0.94–1.24) 1.20 (1.02–1.39)
Age (yr)
,35 3.9 1.58 (1.08–2.32) 2.04 (1.45–2.88) 0.53 (0.32–0.89
35–49 16.7 1.18 (0.94–1.49) 1.45 (1.17–1.78) 0.90 (0.70–1.15)
50–69 46.6 1.03 (0.86–1.22) 1.20 (1.03–1.40) 1.28 (1.08–1.52)
701 32.6 1.00 (reference) 1.00 (reference) 1.00 (reference)
White race 82.3 0.91 (0.75–1.11) 0.61 (0.51–0.73) 1.07 (0.87–1.31)
CVD 15.5 1.04 (0.84–1.28) 1.74 (1.45–2.09) 1.99 (1.65–2.41)
Diabetes mellitus 12.8 1.51 (1.22–1.87) 1.27 (1.05–1.54) 0.97 (0.77–1.22)
Obesity 31.3 0.56 (0.47–0.67) 1.47 (1.28–1.70) 0.62 (0.52–0.73)
Hypertension 54.7 0.93 (0.80–1.09) 1.20 (1.05–1.38) 0.82 (0.70–0.95)
Smoking 13.8 0.82 (0.66–1.02) 0.78 (0.64–0.95) 1.14 (0.92–1.41)
Private insurance 47.7 1.31 (1.12–1.53) 1.20 (1.04–1.38) 1.17 (1.00–1.37)
Specialty
Cardiology 7.4 0.75 (0.55–1.04) 0.84 (0.64–1.10) 1.72 (1.29–2.27)
Internal medicine 39.9 1.23 (1.04–1.45) 1.08 (0.93–1.25) 1.53 (1.29–1.81)
Other specialties 14.1 0.38 (0.29–0.51) 0.36 (0.28–0.46) 0.70 (0.54–0.91)
FP/GP 38.3 1.00 (reference) 1.00 (reference) 1.00 (reference)
Region
South 31.3 0.57 (0.46–0.70) 0.78 (0.65–0.94) 0.60 (0.48–0.74)
Midwest 24.6 0.80 (0.66–0.97) 0.68 (0.57–0.82) 0.61 (0.50–0.75)
West 20.4 0.47 (0.38–0.60) 0.62 (0.50–0.76) 0.83 (0.67–1.03)
Northeast 23.4 1.00 (reference) 1.00 (reference) 1.00 (reference)
*Independent effect of each variable controlling for all other variables listed, estimated by multiple logistic regression.
Abbreviations as in Table 2.
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other regions (20.9%, p , 0.001). Cardiologists (37.7%) and
internists (28.5%) were more likely to report lipid-lowering
medications than general practitioners and family physicians
(17.6%) and other physicians (15.0%, p , 0.001). These
patterns persisted and were statistically significant when mul-
tiple potential confounders were accounted for by logistic
regression (Table 3).
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
ductase inhibitors (or statins) were the most commonly used
lipid-lowering medication (49.5% of visits by patients taking
medications), followed by fibrates (33.7%), resins (12.6%),
niacin (11.4%) and probucol (1.6%). Of patients taking med-
ications, 8.3% were taking more than one agent. Multivariate
analysis suggested that statin use was more common in patients
with cardiovascular disease (adjusted odds ratio [OR] 1.66,
95% CI 1.20 to 2.28), whereas fibrate use was more common in
diabetic patients (adjusted OR 1.61, 95% CI 1.05 to 2.45).
For patients with reported hyperlipidemia, we estimated
national, population-based rates of screening, counseling and
pharmacologic treatment. On the basis of our estimate of 23
million adults with known hyperlipidemia in the United States,
we calculate that in this population, cholesterol testing aver-
ages 0.42 times per person per year. Cholesterol counseling
averages 0.64 episodes per person per year. As described
above, lipid-lowering medications are reported in 23.1% of
visits by patients with known hyperlipidemia.
New visits and general medical examinations. Analysis of
visits for general medical examinations and first visits was
undertaken because these visits are more likely to represent
self-contained episodes of care. These visits constituted 5.1%
of all visits in the United States in 1991 and 1992. For patients
without hyperlipidemia, 12.3% of visits had cholesterol screen-
ing, and 2.1% received cholesterol counseling. The most
consistent predictors of screening and counseling were cardio-
vascular disease risk factors, private insurance and age 35 to 59
years. For visits by patients with hyperlipidemia, 42% had
cholesterol testing, 47% received cholesterol counseling, and
25% were taking lipid-lowering medications. Testing was pos-
itively associated with white race and age ,35 years. Counsel-
ing was associated with nonwhite race, obesity and family
physician/general practitioner visits. Lipid-lowering medica-
tions were associated with private insurance, hypertension and
internist/cardiologist visits. These findings are generally similar
to those noted above for all patient visits.
Discussion
Tasks related to cholesterol management play a substantial
role in the clinical work of American physicians. Practices
relating to cholesterol testing, cholesterol counseling and
lipid-lowering medications are influenced by a wide range of
clinical and nonclinical factors.
Of .1 billion office visits in 1991 and 1992, 8% involved
testing for cholesterol, advice about cholesterol or lipid-
lowering medications. These visits imply the investment of
substantial resources of physician work, laboratory expenses
and medication costs. However, our estimate that only 1 in 12
patients without known hyperlipidemia is screened annually
for cholesterol is well below the 1 in 5 rate expected from the
NCEP’s guideline of screening every 5 years (9). In addition,
our data suggest that patients with hyperlipidemia are coun-
seled about cholesterol reduction at a mean rate of only 34%
annually, or once every 3 years. These results suggest that
physicians have not fully adopted widely recommended cho-
lesterol management practices. More aggressive screening,
counseling and medication treatment for hyperlipidemia would
be expected to have substantial benefits in the primary (31) and
secondary prevention (32) of cardiovascular disease.
Cholesterol management practices contrast with the more
aggressive practices undertaken for hypertension. Data from
the 1991 NAMCS indicate that blood pressure measurement
was performed in 51% of all physician office visits and that
53% of hypertensive patients were treated with antihyperten-
sive medications (33).
Clinical and demographic determinants of practices. Clin-
ical and demographic factors strongly influence patterns of
cholesterol management. As expected, cardiovascular disease
or risk factors for cardiovascular disease led to more aggressive
practices, consistent with published guidelines (8,9). The pres-
ence of cardiovascular disease, diabetes, hypertension and
obesity was frequently associated with a greater likelihood of
cholesterol management services. However, even with cardio-
vascular disease, screening and counseling were relatively
infrequent.
A surprising finding was that obese patients with hyperlip-
idemia were less likely to receive cholesterol monitoring and
lipid-lowering medications. The 1988 NCEP guidelines (8)
(although not the 1993 guidelines [9]) include obesity as a risk
factor that should prompt more aggressive therapy. One
explanation for the less aggressive treatment of obese patients
may be that physicians rely on weight loss, rather than medi-
cations, as a primary management strategy. Consistent with
this explanation, we found obese hyperlipidemic patients more
likely to receive cholesterol counseling than nonobese patients.
Smoking had an unexpected lack of association with choles-
terol management practices. This pattern suggests that physi-
cians may fail to appreciate the powerful synergistic effect of
multiple risk factors and the need for intensive risk factor
modification in patients with more than one risk factor (3).
The youngest patients were less aggressively screened.
Once diagnosed with hyperlipidemia they were more likely to
be counseled but less likely to receive medications. This finding
is consistent with reservations expressed regarding the net
benefits of long-term medication treatment in younger patients
(5). Practices in patients 50 to 69 and .70 years old were
similar, although cholesterol management in the elderly re-
mains controversial (34). Gender differences noted in this
study were small.
Nonclinical determinants of practices. Variations in cho-
lesterol management practices by payment source, geographic
region and physician specialty also raise concerns. Such varia-
tions in clinical practice are often assumed to exist but have not
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been substantiated on a national basis with adjustment for
potential confounders. Most strikingly, we observed that pa-
tients with private insurance received more aggressive choles-
terol management than patients without private insurance.
This finding is consistent with past reports linking lower
socioeconomic status to less aggressive management, particu-
larly for costly services (18).
Patients visiting physicians in the Northeast region of the
nation also received more aggressive cholesterol management
than patients elsewhere. Pilote et al. (35) demonstrated a
similar pattern of higher rates of appropriate medication use
after myocardial infarction in New England. Internists in the
NAMCS sample practiced more aggressively than general
practitioners and family physicians, confirming and augment-
ing a pattern observed for cholesterol testing by Cherkin et al.
(17). Possible explanations for these identified variations in
clinical practice deserve further attention.
Patterns by race were inconsistent. After controlling for
insurance coverage and other potential confounders, whites
were more likely to be screened for hyperlipidemia, but
nonwhites were more likely to receive cholesterol counseling.
Although race did not consistently affect the aggressiveness of
cholesterol management, different patterns of care may exist
for whites and nonwhites.
Use of statins or fibrates were reported in 83.2% of the
visits by patients taking lipid-lowering medications. However,
the 1988 NCEP lists resins and niacin as the drugs of first
choice (8). Current guidelines (9) continue to favor resins and
niacin, although less strongly. Patterns of medication use may
reflect both physician prescribing behavior as well as differen-
tial rates of medication discontinuation (36).
Study limitations. The NAMCS data have several limita-
tions. Although this analysis is based on a representative,
national sample of office-based practices, it is not possible to
determine appropriateness or specific content of these prac-
tices. In particular, the nature of reported cholesterol counsel-
ing may vary between patients or physicians. As a cross-
sectional survey, screening and counseling services have been
evaluated on the basis of visits rather than for patients over
time. Although patients seen more frequently may be less
likely to receive services in any single visit, our analysis of visits
by new patients and visits for general medical examinations
suggests that this bias is unlikely to alter our findings substan-
tially. The observed prevalence of several cardiovascular dis-
ease risk factors is lower than that reported elsewhere, sug-
gesting that physicians are either unaware of their presence or
incompletely report them. Combining NAMCS and NHANES
III data also has potential drawbacks. Our estimated screening
and counseling rates may underestimate actual rates, because
nonphysician and community services are not included in
NAMCS. However, the importance of physicians in coordinat-
ing cardiovascular disease prevention suggests the validity of
focusing on physician office-based services.
Conclusions. The critical importance of cardiovascular dis-
ease demands that effective prevention strategies be utilized
uniformly. Primary and secondary prevention of cardiovascular
disease through screening and treatment of hyperlipidemia is a
crucial but underutilized clinical approach. These national data
on cholesterol management suggest that appropriate clinical
and demographic factors play a role in shaping physician
practices. However, our analysis simultaneously raises con-
cerns about the role of nonclinical factors, particularly pay-
ment source, geographic region and physician specialty. Vari-
ations in these factors reflect potential barriers to the adoption
of recommended practices and warrant further investigation
and explanation.
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